Evolving role of high dose stem cell therapy in multiple myeloma.

about

Evolving role of high dose stem cell therapy in multiple myeloma.

Item

http://www.wikidata.org/entity/Q42287525

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Evolving role of high dose stem cell therapy in multiple myeloma.

@en

Evolving role of high dose stem cell therapy in multiple myeloma.

@nl

type

Item

label

Evolving role of high dose stem cell therapy in multiple myeloma.

@en

Evolving role of high dose stem cell therapy in multiple myeloma.

@nl

prefLabel

Evolving role of high dose stem cell therapy in multiple myeloma.

@en

Evolving role of high dose stem cell therapy in multiple myeloma.

@nl

P1476

Evolving role of high dose stem cell therapy in multiple myeloma.

@en

P2093

Ajay Gupta

http://www.w3.org/2001/XMLSchema#string

Lalit Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.

Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.

Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.

Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Randomized trial experience of the Intergroupe Francophone du Myélome.

P304

17-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/0971-5851.81885

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21731211

http://www.w3.org/2001/XMLSchema#string

P932

3124984

http://www.w3.org/2001/XMLSchema#string